EUVIMEDEUVIMED entdecken
Crossref

Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis

Barbara Mora iD, Francesca Palandri iD, Paola Guglielmelli iD, Andrew T Kuykendall iD, Margherita Maffioli iD, Alessandra Iurlo iD, Valerio De Stefano iD, Silvia Salmoiraghi, Timothy Devos iD, Federico Itri iD, Francisco Cervantes, Jean-Jacques Kiladjian iD und 26 weitere

Blood · 2026

DOI: 10.1182/blood.2025031366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2026. Verfasst von Barbara Mora und 37 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Polycythemia Vera, Primary Myelofibrosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secondary myelofibrosis (SMF) represents a late stage of polycythemia vera (PV) and essential thrombocythemia (ET), with overall survival (OS) currently defined by the myelofibrosis secondary to PV and ET prognostic model (MYSEC-PM). To identify additional myeloid neoplasm–associated cancer gene variants (CGVs) associated with SMF outcome, we evaluated next-generation sequencing panel testing in 644 patients within the MYSEC cohort. Overall, 429 (66.6%) patients reported at least 1 CGV, with ASXL1, TET2, and DNMT3A being the most frequently involved. Specific molecular profiles affected OS (P< .001): U2AF1, TP53, or SRSF2 variants (UTS; 9.3%; median OS, 4.1 years) and ASXL1 without UTS (25.3%; median OS, 8.4 years). By integrating these genetic signatures within the MYSEC-PM through penalized Cox regressions, we identified the following independent predictors (P< .0001 to .02): hemoglobin level <11 g/dL (1 point), circulating blasts ≥3% (2 points), platelet count <150 × 109/L (2 points), age (0.21 points/y), ASXL1 without UTS mutations (1 point), and any UTS mutations (3 points). Finally, we developed the MYSEC-molecular prognostic model (MYSEC-mPM) allocating 582 patients with SMF into 4 categories with different OS (P < .001): low (median OS, 18.0 years; score <14), intermediate-1 (8.8. years; score, 14-16), intermediate-2 (4.6 years; score, 17-18), and high risk (1.9 years; score ≥19). Additionally, in 381 patients with SMF and available cytogenetics, the MYSEC-mPM was implemented with complex/monosomal karyotype, generating the karyotype-enhanced MYSEC-kmPM. Our study shows that genomic and cytogenetic profiling improves survival prediction in SMF, outperforming the MYSEC-PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocythemia, EssentialPolycythemia VeraPrimary MyelofibrosisHumansFemaleMaleAgedPrognosisMiddle AgedAged, 80 and overAdultClinical Decision-Making

Autor:innen und Institutionen

  • Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Seragnoli Hematology Institute, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.
  • Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Hematology, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.
  • Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

ORCID-Profile: Barbara Mora, Francesca Palandri, Paola Guglielmelli, Andrew T Kuykendall, Margherita Maffioli, Alessandra Iurlo, Valerio De Stefano, Timothy Devos, Federico Itri, Jean-Jacques Kiladjian, Matteo G Della Porta, Francesco Albano, Giulia Benevolo, Marco Ruggeri, Elisa Rumi, David M Ross, Francesco Orsini, Rami S Komrokji, Patrizia Chiusolo, Tiziano Barbui, Daniela Cilloni, Massimo Breccia, Filippo Branzanti, Ludovica Margotto, Matteo Franchi, Alessandro M Vannucchi, Francesco Passamonti

Zitieren

APA

Mora, B., Palandri, F., Guglielmelli, P., Kuykendall, A. T., Maffioli, M., Iurlo, A., De Stefano, V., Salmoiraghi, S., Devos, T., Itri, F., Cervantes, F., Kiladjian, J. J., Della Porta, M. G., Albano, F., Gotlib, J., Benevolo, G., Caramella, M., Ruggeri, M., Rumi, E., …, & Passamonti, F. (2026). Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis. Blood. https://doi.org/10.1182/blood.2025031366

Vancouver

Mora B, Palandri F, Guglielmelli P, Kuykendall AT, Maffioli M, Iurlo A, et al. Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis. Blood. 2026. doi:10.1182/blood.2025031366

BibTeX
@article{Mora2026,
  author = {Mora, Barbara and Palandri, Francesca and Guglielmelli, Paola and Kuykendall, Andrew T and Maffioli, Margherita and Iurlo, Alessandra and De Stefano, Valerio and Salmoiraghi, Silvia and Devos, Timothy and Itri, Federico and Cervantes, Francisco and Kiladjian, Jean-Jacques and Della Porta, Matteo G and Albano, Francesco and Gotlib, Jason and Benevolo, Giulia and Caramella, Marianna and Ruggeri, Marco and Rumi, Elisa and Ross, David M and Pessina, Chiara and Colugnat, Ilaria and Orsini, Francesco and Micucci, Giorgia and Rotunno, Giada and Komrokji, Rami S and Cattaneo, Daniele and Chiusolo, Patrizia and Bortolotti, Marta and Barbui, Tiziano and Cilloni, Daniela and Breccia, Massimo and Palumbo, Giuseppe A and Branzanti, Filippo and Margotto, Ludovica and Franchi, Matteo and Vannucchi, Alessandro M and Passamonti, Francesco},
  title = {Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis},
  journal = {Blood},
  year = {2026},
  doi = {10.1182/blood.2025031366}
}
Kostenlos starten →